Breast Cancer Clinical Trials and Research
At City of Hope, breast cancer clinicians and researchers collaborate extensively to develop and evaluate new therapies for better survival and quality-of-life outcomes. Our patients have access to a wide variety of clinical trials including new chemotherapy and targeted therapies, hormone therapies, novel surgical techniques, innovative radiation approaches and new prevention strategies.
Newly Diagnosed Metastatic Stage 4 Estrogen Receptor Positive Breast Cancer
NCT02778685: Principal Investigator Yuan Yuan, M.D., Ph.D., is actively recruiting patients for a study on the benefits of immunotherapy with monoclonal antibodies, such as pembrolizumab, in patients with newly diagnosed Stage 4 estrogen receptor positive metastatic breast cancer.
Patient Enrollment Qualifications
- Females 18 years of age or older
- Newly diagnosed (cohort 2) Stage 4 metastatic ER+HER2-breast cancer
- Life expectancy of ≥ 3 months
Triple-Negative Breast Cancer
NCT03012100: Principal investigator James R. Waisman, M.D., is actively recruiting for a study on the benefits of multi-epitope folate receptor alpha peptide vaccine, GM-CSF and cyclophosphamide in treating patients with triple-negative breast cancer.
Patient Enrollment Qualifications
- Females 18 years of age or older
- Resected unilateral or bilateral primary carcinoma of the breast without clinical evidence of metastatic disease
- Negative for estrogen receptor and progesterone receptor, and negative for HER2
- Completed planned breast cancer surgeries, any radiation therapy and any chemotherapy ≥ 90 days, but not ≥ 546 days prior to randomization
Hormone Receptor Positive Metastatic Breast Cancer
NCT04305834: Principal investigator Mina S. Sedrak, M.D., M.S., is actively recruiting for a study on the benefits of abemacicilib monotherapy in treating patients aged 70 years or older with hormone receptor positive, HER2 negative breast cancer that has spread to other parts of the body.
Patient Enrollment Qualifications
- Females 70 years of age or older
- Measurable or nonmeasurable disease
- Life expectancy > 6 months
Healthy Volunteers and Patients With Breast Cancer-Related Upper Limb Secondary Lymphedema
NCT04243837: Principal investigator Alex K. Wong, M.D., is actively recruiting for a study to determine the best dose of LYT-500 in healthy volunteers, followed by a study in patients with breast cancer-related upper limb secondary lymphedema.
Patient Enrollment Qualifications
- Healthy male or female volunteers between 18 and 75 years old
- Males or females between 18 and 80 years old with breast cancer-related lympedema
- At least six months since any type of breast cancer surgery
Metastatic Breast Cancer
NCT04699630: Principal investigator Yuan Yuan, M.D., Ph.D., is actively recruiting patients for a study on the benefits of antibody drug conjugate U3-1402 in patients with metastatic breast cancer (MBC) who have received no prior anti-HER2 therapy.
Patient Enrollment Qualifications
- 18 years of age or older
- Histologically documented locally advanced or metastatic breast cancer
- Patients having received at least one, but no more than three prior lines of chemotherapy in a metastatic setting
To refer a patient to one of our clinical trials, please call 626-218-1133 or visit CityofHope.org/Clinical-Trials.
